GPBAR1 and myeloid sarcoma: The potential for targeting TGR5 in alleviating MS was also demonstrated in another study, where treatment with GPBAR1/TGR5 small molecule agonist exhibited a significant reduction in the EAE clinical score, which correlated with reduced monocyte and microglial activation, as well as reduced trafficking of monocytes and T cells into the CNS [92].